地舒单抗治疗骨转移的效果如何？

In November 2010, denosumab (also known as denosumab) was approved to prevent bone-related events in patients and to treat bone metastases from solid tumors. Desosumab is the first RANKL inhibitor approved by the FDA under the trade name Xgeva. On June 13, 2013, the U.S. FDA approved denosumab for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or in which resection would result in significant morbidity.

How effective is denosumab in the treatment of bone metastases?

DEFEND (Denosumab Fortifies Bone Density), a randomized, placebo-controlled, phase III clinical trial, evaluated denosumab (denosumab) in preventing osteoporosis in postmenopausal women. The average age of the subjects was 59.4 years old, and the spine T-scores were between -1.0 and -2.5 (the average was -1.61). They were randomly divided into a treatment group (desosumab 60 mg subcutaneous injection, once every 6 months, n=166) or a placebo group (n=166). All patients were supplemented with 1000 mg of calcium every day, and the level of plasma 25-hydroxyvitamin D in the subjects was used to determine whether vitamin supplements were needed. D. The main evaluation index is the change in spinal BMD measured by dual energy X-ray absorptiometry (DXA) compared with the baseline level.

The results showed that after 24 months, denosumab significantly increased spinal BMD values compared with placebo (a 6.5% increase in the treatment group versus a 0.6% decrease in the placebo group). In addition, the BMD values ​​of all tested parts such as the hip bone and distal radius in the treatment group increased significantly. At the same time, markers of bone resorption and formation were significantly reduced. The overall incidence of adverse reactions in the treatment group was similar to that in the placebo group during the observation period.

To sum up, the treatment effect of (denosumab) is remarkable and it is a good choice for patients.